文献速递精神分裂症与精神病性障碍

精神分裂症风险基因SETD1A突变导致人神经元突触功能失调

Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons.
PubMed 文献 · Mol Psychiatry · 2025-09-17

该研究利用CRISPR/Cas9构建携带SETD1A罕见提前终止突变的iPSCs,并分化为兴奋性神经元。突变导致mRNA经无义介导衰变降解、蛋白单倍剂量不足,进而改变树突复杂性、突触传递和可塑性,为SETD1A单倍剂量不足与精神分裂症病理机制提供见解。

要点

  • SETD1A罕见提前终止突变经NMD降解mRNA,导致SETD1A蛋白单倍剂量不足。
  • SETD1A+/-突变改变人兴奋性神经元树突复杂性和突触传递。
  • 突触功能相关基因失调可能是SETD1A+/-相关精神分裂症病理机制。

核心结论

  • SETD1A+/-外显子16功能丧失突变通过NMD降解mRNA导致单倍剂量不足,并改变人兴奋性神经元形态与突触功能。

研究设计与样本

  • 研究用CRISPR/Cas9工程化五对人iPSCs等基因对,两株供体携带复发性杂合突变c.4582-2delAG,三株携带杂合移码突变c.4596_4597insG(p.Leu1533fs)。
  • 将iPSCs经NGN2诱导分化为人类兴奋性神经元,进行形态学、电生理和转录组学表征。

主要发现

  • 两种突变预测在外显子16产生提前终止密码子,导致SETD1A单倍剂量不足。
  • 这些功能丧失突变使SETD1A mRNA经无义介导衰变降解,并降低iPSCs中全长SETD1A蛋白水平。
  • SETD1A+/-外显子16功能丧失突变改变树突复杂性、失调突触传递和突触可塑性,可能通过失调突触功能相关基因实现。

临床怎么用

  • SETD1A单倍剂量不足可能作为精神分裂症风险标志,但尚需临床验证。

局限性

  • 研究仅基于iPSC衍生神经元体外模型,未涉及人体或临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schizophrenia (SCZ) is a complex neuropsychiatric disorder associated with both common risk variants of small effect sizes and rare risk variants of high penetrance. Rare premature open reading frame (ORF) termination variants in SETD1A (SET Domain Containing 1A) show a strong association with SCZ; however, it remains largely unclear how rare premature ORF termination variants in SETD1A contribute to the pathophysiology of SCZ. To understand the impact of SETD1A rare premature ORF termination variants in human neurons, we CRISPR/Cas9-engineered five isogenic pairs of human induced pluripotent stem cells (iPSCs), with a recurrent heterozygous patient-specific premature ORF termination mutation c.4582-2delAG in two donor lines and a heterozygous frameshift mutation c.4596_4597insG (p. Leu1533fs) in three donor lines. These two mutations are predicted to cause a premature stop codon in exon 16 of SETD1A, leading to SETD1A haploinsufficiency. We found that these presumably loss-of-function (LoF) mutations caused the SETD1A mRNAs to be degraded by nonsense-mediated decay (NMD), accompanied by a reduction of full-length SETD1A protein level in iPSCs. We then characterized the morphological, electrophysiological, and transcriptomic impacts of SETD1A+/- LoF mutations in iPSC-derived human excitatory neurons induced by NGN2. We found that the SETD1A+/- exon-16 LoF mutations altered dendrite complexity, dysregulated synaptic transmission, and synaptic plasticity, likely by dysregulating genes involved in synaptic function. These results provide mechanistic insights into how SETD1A+/- exon-16 patient-specific LoF mutations affect neuron phenotypes that may be relevant to the pathophysiology of SCZ.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Su X, Zhang H, Hong Y, et al. Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons. Mol Psychiatry. 2025. PMID: 40962831. doi:10.1038/s41380-025-03246-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。